In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs Greg Scott joined Foley's Eye on China webinar on life science innovation >>Foley webinar...
|
3SBio’s Q3 Hurt by Lehman Bankruptcy
publication date: Nov 3, 2008
3SBio Inc. announced a $2.7 million writedown as a consequence of the US financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers bankruptcy, the notes have been given a value of $300,000. 3SBio made the announcement as part of its preliminary Q3 unaudited results. The company said its Q3 revenues climbed 22% to 68.2 million RMB ($10.0 million). However, because of the charge, net income dropped to 1.9 million RMB ($0.3 million), or $0.01 per ADS. More details...
Stock Symbol: (NSDQ: SSRX)
|
Partner Events
BioPharm America™ 2010Boston, MA, USA September 15–17, 2010 CALAsia 2010San Diego, USA October 4-5, 2010 CHINA PRETRIALS 2010: Global Preclinical Development Summit Beijing, China October 17-19, 2010 CHINA TRIALS 2010 Beijing, China November 7-9, 2010 12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Beijing, China November 9-11, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|